Brainstorm Cell Therapeutics Inc.
BCLI · OTC
Bulios Fair Price
$0.99
13.8% upside
Current Price
$0.87
According to Bulios Fair Price, BCLI is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company focused on researching and developing therapies for neurological disorders. The company specializes in utilizing its proprietary technologies and methods for treating and improving the quality of life for patients suffering from neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Brainstorm Cell Therapeutics is developing innovative cell-based therapeutic approaches that offer hope for improving the health of those grappling with these serious diseases. Investors interested in the biotechnology sector and medical research may find the shares of Brainstorm Cell Therapeutics Inc. (BCLI) to be an intriguing investment opportunity.
Sector
Healthcare
Industry
Biotechnology
CEO
Chaim Lebovits
Employees
19
Headquarters
New York City
Upcoming events
Earnings
Upcoming earnings report